{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-001198","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.966531+00:00","generated_at":"2026-06-07T02:06:32.932587+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"ADMA Biologics furnishes January 2024 corporate presentation; no specific financial or operational updates disclosed","bullets":["Filing furnishes a corporate presentation under Item 7.01 Regulation FD.","Presentation titled 'Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology'.","No earnings, guidance, or material business developments provided in the exhibit.","Presentation is available on ADMA's website under Investors section."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-001198","json":"https://secwatch.observer/filing/0001140361-24-001198.json","markdown":"https://secwatch.observer/filing/0001140361-24-001198.md","text":"https://secwatch.observer/filing/0001140361-24-001198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124001198/0001140361-24-001198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124001198/ef20018277_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:06:32.932587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}